C. diff Colonisation and Risk for Subsequent Infections
“Importantly in this study, colonisation with toxigenic C. difficile on admission was identified as a strong and independent predictor for development of subsequent [C. difficile infection,]” say Trish M. Perl, MD, MSc, of the Johns Hopkins University School of Medicine, and co-authors.
The prospective cohort study was conducted from April to July 2013. Adult patients (n = 542) were screened for C. difficile within 48 hours of admission to the ICU at Johns Hopkins Hospital (Baltimore, MD). Rectal swabs were used to screen for C. difficile at admission and weekly until ICU discharge. Patients also were monitored by medical chart review for one month after discharge.
Dr. Perl and colleagues found that 17 patients (3.1 percent) admitted had toxigenic C. difficile colonisation on admission, and an additional three patients had a subsequent C. difficile infection during weekly follow-up. Colonisation with toxigenic C. difficile before admission was associated with developing infection (RR = 10.29; 95% CI, 2.24–47.4), as was colonisation during hospitalisation (RR = 15.66; 95% CI, 4.01–61.08). After adjusting for confounders, the researchers found colonisation before admission (RR = 8.62; 95% CI, 1.48–50.25) and during hospital stay (RR = 10.93; 95% CI, 1.49–80.2) were independent risk factors for infection.
Age, use of proton pump inhibitors or antibiotics or prior healthcare visits up to 12 weeks were not associated with C. difficile infection, the Johns Hopkins team notes. During their hospital stays, 1.5 percent of patients developed C. difficile infection; four patients were diagnosed within one month of discharge.
The study suggests that traditional infection control measures "may not suffice to avoid further increase in disease burden," the researchers point out. "For patients colonised with toxigenic C. difficile, the challenge for disease prevention is not to prevent exposure but to reduce the risk of C. difficile toxin expression by restricting use of antibiotics, acid-suppressive agents and narcotics,” they add.
Source: Johns Hopkins University School of Medicine
Image credit: Flickr.com
Published on : Tue, 18 Aug 2015
Print as PDF
17 critical parameters from a blood sample as small as 45 µL Not available in the US When the sample is small but your diagnostic needs are big, the ABL90 FLEX PLUS blood gas analyzer provides critical insights with a turnaround time of less than...
FeaturesMindray BeneVision Central Monitoring System is a powerful and scalable solution providing for continuous, real-time surveillance across networks large and small. The system can display patient information from networked monitors, wireless transport...
NovaPort cannulas: The safe access to the vascular system. NovaPort® twin double lumen cannulas are specifically developed for veno-venous vascular access. NovaPort one single lumen cannulas are specifically developed for the percutaneous connection (KU)...